药物释放型球囊市场（按应用、药物类型、最终用户、产品类型和分销管道）—全球预测 2025-2032

预计到 2032 年药物释放型球囊市场将成长至 36.6 亿美元，复合年增长率为 16.24%。

全面说明药物释放型球囊的动态，并重点介绍当前医疗环境中的临床前景、设备创新和商业性压力

随着器械创新者、介入专家和支付方重新评估血管疾病临床治疗路径，药物释放型球囊领域正迎来曲折点。这一趋势融合了加速的技术进步、更严格的监管审查以及不断发展的医疗经济，所有这些对相关人员都至关重要。在此背景下，药物释放型球囊因其无需留下永久植入物即可进行抗增殖治疗的潜力，正重新引起人们的注意。

临床应用正受到以下因素的影响：需要解决不同类型的冠状动脉和周边病变，并填补有关长期疗效和安全性讯号的现有证据空白。同时，製造商正在改进药物输送系统、辅料和下游物流，以提高药物传输效率，最大限度地降低栓塞风险，并简化手术流程。这些渐进式改进正在创造差异化的价值提案，尤其是在避免使用永久性金属支架具有临床优势的病变亚群中。

从商业性角度来看，采购商和医院正在评估整体手术成本、长期器械相关併发症的潜在减少量以及对医疗转型的影响。付款人和医疗采购团队要求临床价值与报销之间紧密结合，因此公司必须提供清晰的比较效益证据。这种采用为深入研究转型转变、资费影响、细分动态、区域差异、竞争定位以及后续分析的实用建议奠定了基础。

涂层化学、临床试验设计和临床实践的进步如何同时改变药物释放型球囊的患者选择和销售管道

随着技术、临床证据生成和医疗服务模式的融合，药物释放型球囊领域正在经历一场变革。技术进步的重点是优化涂层化学成分、赋形剂以及球囊表面工程，以增强药物的保留和向血管壁的均匀输送。这些技术进步，加上输送导管设计的不断改进，以适应曲折和远端入路，正在扩大球囊治疗的适应病变范围。

同时，临床试验架构正转向头对头比较研究，强调以患者为中心的终点，例如生活品质、再灌注需求以及週边介入治疗中的肢体挽救。来自註册研究和上市后监测的真实世界证据也被纳入其中，以补充随机数据，支持对细微适应症和亚群的分析。因此，分层证据正在指导冠状动脉应用（包括新发病变和支架内血管再阻塞）以及週边应用（区分膝下和股腘动脉区域）的应用。

市场管道和医疗保健环境正在根据不断变化的经济状况和手术复杂性进行调整。门诊手术中心正在提升其支持微创手术的能力，从而创造机会将某些手术从住院医院转移出去。同时，设备开发商和分销合作伙伴之间的策略联盟正在加速产品覆盖范围，同时使製造商能够专注于临床开发和监管策略。总而言之，这些转变正在重塑竞争优势，提高临床检验的标准，并强调将设备性能与证据生成和报销支援相结合的综合提案主张。

预计 2025 年的关税压力将迫使製造商优化供应链和筹资策略，同时保留临床价值提案

美国将于2025年加征关税，这对药物释放型球囊製造商和采购商而言，是关键的商业性考量因素，将影响其采购、定价和供应链韧性。进口零件和成品关税导致成本增加，这促使製造商重新评估其全球製造地、供应商合约条款和对冲策略，以减轻利润压缩的影响。同时，医院、诊所和门诊手术中心的采购团队正在重新评估其供应商选择标准，并将潜在的价格波动和总到岸成本纳入考量。

鑑于关税的影响，一些公司正在加速关键製造流程的在地化，或在免税地区寻找替代供应商，以保持成本竞争力。另一些公司则正在重新审视其销售合约和服务模式，以平衡营运成本限制和库存。这些商业决策不仅受制于直接的成本影响，也受到智慧财产权保护、监管协调和供应商风险集中等长期策略考量。

根据产品类型及其供应链架构，临床医生和管理人员可能会看到各种结果。对于依赖商品化组件的传统球囊，利润压力可能反映在价格谈判和转向主导的采购模式上。对于技术含量高且具有专有涂层的特种球囊，製造商可能会承担部分关税成本以保护其市场地位，同时试图透过展示临床效用来证明溢价的合理性。关税驱动的动态凸显了供应链透明度、自适应筹资策略以及与付款人和采购相关人员积极互动的重要性，以使价值预期与不断变化的成本结构保持一致。

策略性细分的必要性显示了应用、药物化学、护理环境、产品差异化和通路选择如何决定采取路径。

细分洞察揭示了不同应用领域、药物类型、最终用户、产品类型和分销管道之间存在的细微机会和限制因素，需要製定有针对性的策略，而非一刀切。在冠状动脉领域，临床医师在选择球囊治疗方案时会区分新生血管性病变和支架内再血管再阻塞；而在周边动脉领域，由于病变形态和临床目标的显着差异，临床医师会将膝下段和股腘动脉段区分开来。这些临床细分领域决定了器材设计需求、证据需求和术后追踪路径。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 采用新型无聚合物药物涂层减少药物释放型球囊手术中的晚期不利事件
• Sirolimus洗脱球囊技术扩大了周边动脉疾病患者的治疗选择
• 透过将血管内影像导引系统与药物释放型球囊治疗方法结合，准确评估病变
• 医疗设备製造商与製药公司建立策略伙伴关係，优化球囊药物输送
• 增加对微孔技术的投资，以提高球囊血管成形术干预期间的局部药物传输效率
• 更重视卫生经济学和报销策略，以改善药物释放型球囊设备的市场进入
• 由于周边动脉疾病发病率上升和医疗基础设施改善，亚太市场将快速成长

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章药物释放型球囊市场（依应用）

• 冠状动脉疾病
  • 新的病变
  • 支架内血管再阻塞
• 周边动脉疾病
  • 膝盖以下
  • 股腘肌

第九章药物释放型球囊市场（依药物类型）

• 紫杉醇涂层
• Sirolimus涂层

第 10 章药物释放型球囊市场（依最终用户）

• 门诊手术中心
• 诊所
• 医院

第11章药物释放型球囊市场（依产品类型）

• 常规气球
• 特殊气球

第十二章药物释放型球囊市场（依通路）

• 直接地
• 批发商

第十三章药物释放型球囊市场（依地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章药物释放型球囊市场：依类别

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章药物释放型球囊市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Medtronic plc
  • Boston Scientific Corporation
  • B. Braun SE
  • Koninklijke Philips NV
  • Becton Dickinson and Company
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Concept Medical Research Private Limited

The Drug Eluting Balloon Market is projected to grow by USD 3.66 billion at a CAGR of 16.24% by 2032.

A comprehensive orientation to drug eluting balloon dynamics that situates clinical promise, device innovation, and commercial pressures in the current healthcare environment

The drug eluting balloon landscape is at an inflection point as device innovators, interventionalists, and payers reassess clinical pathways for vascular disease management. This introduction frames the essential context for stakeholders who must navigate accelerating technological refinement, heightened regulatory scrutiny, and evolving care-site economics. Against this backdrop, drug eluting balloons are attracting renewed attention for their potential to deliver antiproliferative therapy without leaving a permanent implant, which has important implications for patient management strategies and follow-up care patterns.

Clinical adoption is being shaped by the need to address heterogeneous lesion types across coronary and peripheral territories, and by the imperative to close evidence gaps that persist around long-term outcomes and safety signals. At the same time, manufacturers are refining delivery systems, excipients, and downstream logistics to improve drug transfer efficiency, minimize embolic risk, and streamline procedural workflows. These incremental improvements are creating differentiated value propositions, particularly for lesion subsets where avoiding permanent metallic scaffolds is clinically advantageous.

From a commercial perspective, purchasers and hospitals are evaluating total procedure cost, potential reductions in long-term device-related complications, and implications for care setting migration. As payers and institutional procurement teams demand tighter alignment between clinical value and reimbursement, companies must articulate clear evidence of comparative benefits. This introduction sets the stage for a deeper examination of transformative shifts, tariff influences, segmentation dynamics, regional variance, competitive positioning, and pragmatic recommendations that follow in this analysis.

How simultaneous advances in coating chemistry, clinical trial design, and care-site migration are reshaping patient selection and commercial pathways for drug eluting balloons

The drug eluting balloon domain is experiencing transformative shifts driven by converging forces in technology, clinical evidence generation, and care delivery models. Technological evolution centers on coating chemistries, excipient optimization, and balloon surface engineering to enhance drug retention and uniform transfer to the vessel wall. These technical refinements are accompanied by iterative improvements in delivery catheter design to address tortuosity and distal access, which together broaden the range of lesions amenable to balloon-based therapy.

Concurrently, clinical trial architecture is shifting toward head-to-head comparative studies that emphasize patient-centered endpoints such as quality of life, need for repeat revascularization, and limb salvage in peripheral interventions. The community is also incorporating real-world evidence from registries and post-market studies to complement randomized data, thereby supporting nuanced indications and subpopulation analyses. As a result, adoption is being guided by evidence stratified across coronary applications including de novo lesions and in-stent restenosis, as well as peripheral applications that differentiate below knee and femoropopliteal territories.

Market channels and care settings are adjusting in response to evolving economics and procedural complexity. Ambulatory surgical centers are increasingly capable of supporting minimally invasive interventions, creating opportunities to shift certain procedures out of inpatient hospital settings. At the same time, strategic partnerships between device developers and distribution partners are accelerating product reach while allowing manufacturers to focus on clinical development and regulatory strategy. Collectively, these shifts are reconfiguring competitive advantage, raising the bar for clinical validation, and emphasizing integrated value propositions that combine device performance with evidence generation and reimbursement support.

Projected tariff pressures in 2025 compelling manufacturers to optimize supply chains and procurement strategies while protecting clinical value propositions

The imposition of United States tariffs scheduled for implementation in 2025 introduces a material commercial consideration for manufacturers and purchasers of drug eluting balloons, with implications across sourcing, pricing, and supply chain resilience. Tariff-driven cost increases for imported components or finished devices are prompting manufacturers to re-evaluate global manufacturing footprints, contract terms with suppliers, and hedging strategies that can mitigate margin compression. In parallel, procurement teams within hospitals, clinics, and ambulatory surgical centers are reassessing vendor selection criteria to account for potential price volatility and total landed cost.

In anticipation of tariff effects, some companies are accelerating localization of critical manufacturing steps or qualifying alternative suppliers in tariff-exempt jurisdictions to preserve cost competitiveness. Others are revisiting distribution agreements and service models to balance inventory positioning against working capital constraints. These operational decisions are informed not only by immediate cost impacts but also by longer-term strategic considerations such as intellectual property protection, regulatory harmonization, and supplier risk concentration.

Clinicians and administrators will likely see differentiated outcomes depending on product type and supply chain architecture. For conventional balloons that rely on commoditized components, margin pressure may translate into pricing negotiations or shifts toward distributor-led procurement models. For specialty balloons with higher technical content and proprietary coatings, manufacturers may absorb a degree of tariff-induced cost to protect market positioning, while seeking to justify premium pricing through demonstrated clinical benefit. Ultimately, tariff-driven dynamics underscore the importance of supply chain transparency, adaptable sourcing strategies, and proactive engagement with payers and procurement stakeholders to align expected value with evolving cost structures.

Strategic segmentation imperatives demonstrating how distinct application, drug chemistry, care setting, product differentiation, and channel choices determine adoption pathways

Segmentation insights reveal nuanced opportunities and constraints across application, drug type, end user, product type, and distribution channel that demand targeted strategies rather than one-size-fits-all approaches. Based on application, adoption patterns diverge between coronary artery disease and peripheral artery disease; within coronary practice, clinicians distinguish between de novo lesions and in-stent restenosis when selecting balloon-based therapy, while peripheral specialists separate decisions for below knee and femoropopliteal segments because lesion morphology and clinical objectives differ markedly. These clinical subsegments shape device design requirements, evidence needs, and post-procedural follow-up pathways.

Based on drug type, the dichotomy between paclitaxel-coated and sirolimus-coated balloons continues to influence investment priorities and clinician perception. Paclitaxel-based platforms remain notable for historical adoption in specific peripheral indications and for established transfer kinetics, while sirolimus-coated systems are gaining traction due to the drug's antiproliferative profile and perceived potential for improved safety in select settings. Manufacturers must therefore align clinical programs and messaging with the pharmacologic attributes and regulatory expectations associated with each drug type.

Based on end user, market dynamics vary across ambulatory surgical centers, clinics, and hospitals, as each care setting has distinct infrastructure, procedural throughput, and purchasing protocols. Ambulatory surgical centers may prioritize devices that streamline workflow and shorten recovery, clinics may focus on devices enabling less invasive outpatient interventions, and hospitals typically evaluate devices within broader service-line economics and capital planning frameworks. Concomitantly, based on product type, conventional balloons and specialty balloons occupy different value tiers; specialty balloons command attention where lesion complexity or adjunctive technology warrants differentiated performance, while conventional balloons remain relevant where cost sensitivity and familiarity drive selection.

Based on distribution channel, strategic choices between direct sales and distributor partnerships affect market access, customer service models, and data feedback loops. Direct engagement can support closer clinical collaboration and tailored training, whereas distributor networks can accelerate regional penetration and reduce operational overhead. Taken together, this segmentation architecture underscores that successful commercialization demands tightly aligned clinical evidence, product differentiation, and distribution strategies that reflect the specific needs of the clinical subsegments and care settings targeted.

Comparative regional dynamics and market access realities illustrating how regulatory nuance, reimbursement policy, and clinical practice shape adoption across global markets

Regional dynamics for drug eluting balloons are shaped by heterogeneous regulatory environments, reimbursement frameworks, and clinical practice patterns across Americas, Europe, Middle East & Africa, and Asia-Pacific, each of which presents distinct opportunities and commercialization challenges. In the Americas, clinical practice emphasizes outcome-driven device selection and robust post-market surveillance, while procurement decision-making tends to weigh long-term value against upfront cost, influencing how manufacturers position evidence and pricing models.

Within Europe, Middle East & Africa, regulatory harmonization efforts coexist with national-level reimbursement policies that create a mosaic of access pathways; manufacturers must therefore calibrate launch sequencing and medical affairs engagement to local HTA and hospital purchasing processes. In the Asia-Pacific region, diverse market maturity and rapid infrastructure investment in urban centers create opportunities for both flagship product launches and localized manufacturing, though region-specific clinical preferences and regulatory timelines require tailored market entry strategies. Transitional considerations across regions include the growing importance of registry data, cross-border clinical collaborations, and the potential for regional centers of excellence to influence wider adoption patterns.

Across all geographies, supply chain robustness and tariff exposure remain central concerns for stakeholders. The interplay between regional reimbursement rules and clinical evidence requirements will continue to shape where and how quickly new drug eluting balloon technologies achieve traction, making strategic regional prioritization a critical component of commercialization planning.

Competitive ecosystem overview emphasizing clinical differentiation, manufacturing partnerships, and evidence-driven commercial execution as determinants of leadership

Competitive dynamics in the drug eluting balloon space reflect a mix of established medical device companies, specialized interventional device innovators, and strategic collaborations that combine clinical expertise with manufacturing scale. Established players leverage broad commercial footprints and integrated salesforces to support hospital adoption, while niche innovators focus on differentiated coating technologies, excipient systems, and catheter performance to win specific lesion segments or care settings. Partnerships between clinical opinion leaders and device developers are becoming more prevalent as a route to accelerate evidence generation and to refine procedural technique training.

Investment in clinical development is increasingly a differentiator; companies that can produce robust, transparent outcome data and real-world registry evidence gain credibility with both clinicians and payers. At the same time, regulatory approvals and post-market surveillance commitments remain a critical determinant of competitive positioning, particularly where historical safety questions or device-specific concerns require active risk mitigation. Mergers, acquisitions, and licensing arrangements are shaping the landscape by consolidating intellectual property and bolstering distribution channels, while contract manufacturers and specialized coating houses play an essential role in scaling production for newer drug formulations.

Commercial execution also hinges on service-oriented capabilities such as procedure training, reimbursement support, and patient selection tools that reduce the friction of adoption. Ultimately, market leadership will favor organizations that combine scientific differentiation with operational excellence in supply chain, clinical evidence generation, and stakeholder engagement.

Actionable strategic priorities for manufacturers and stakeholders to align clinical evidence, supply chain resilience, and tailored commercial models for scalable adoption

Industry leaders should pursue an integrated strategy that aligns product development, clinical evidence, and commercial execution to accelerate sustainable adoption. Prioritize investments in head-to-head and real-world studies that address high-impact clinical endpoints-particularly within the differentiated application subsegments of de novo lesions, in-stent restenosis, below knee disease, and femoropopliteal disease-so that value propositions are clearly supported by context-specific data. In parallel, optimize coating and delivery systems to enhance drug transfer efficiency and minimize downstream embolic risk, placing emphasis on both paclitaxel- and sirolimus-coated platforms depending on the clinical niche targeted.

Adopt a flexible supply chain strategy that balances localized manufacturing options with qualified multi-sourcing to mitigate tariff exposure and component scarcity. Commercially, tailor go-to-market models to end user requirements: design rapid onboarding and streamlined procedural kits for ambulatory surgical centers, create protocolized pathways and training modules for clinics performing outpatient interventions, and equip hospital teams with comprehensive health-economic narratives that address service-line and capital considerations. Leverage direct sales in high-value accounts where clinical partnership is critical, while using distributor relationships to accelerate penetration in fragmented or geographically dispersed markets.

Engage payers early with transparent evidence packages and real-world economic models that articulate long-term clinical and cost outcomes. Finally, invest in post-market surveillance, registry participation, and clinician education to reinforce safety profiles and to support incremental label expansion where clinical evidence permits. These combined measures will strengthen competitive positioning and enable scalable adoption across diverse clinical and regional contexts.

A transparent, mixed-methods research framework combining clinician interviews, technical assessments, and supply chain analysis to validate strategic insights

This research synthesis is grounded in a mixed-methods approach that triangulates multiple sources of evidence to ensure robustness and applicability. The methodology integrates targeted interviews with interventional cardiologists, vascular specialists, procurement leaders, and distribution partners to capture practitioner perspectives and procurement imperatives. These primary insights are complemented by a systematic review of peer-reviewed clinical literature, regulatory filings, and post-market surveillance reports to contextualize efficacy and safety signals across indications and drug chemistries.

Device design and manufacturing assessments draw on technical literature, patent landscapes, and expert consultations to evaluate coating technologies, excipient strategies, and catheter system innovations. Supply chain analysis was informed by discussions with manufacturers and logistic providers to map sourcing dependencies, tariff exposure, and manufacturing localization options. Commercial and reimbursement insights derived from interviews with hospital administrators, ambulatory surgical center managers, and payers provide pragmatic perspectives on procurement cycles, contracting preferences, and value argumentation.

Throughout the research, findings were validated via cross-checking among independent expert reviewers and through iterative reconciliation of primary and secondary sources. Where uncertainties or divergent viewpoints emerged, sensitivity analyses and scenario-based reasoning were applied to highlight risks and contingent strategies rather than to produce numerical forecasts. The methodology emphasizes transparency, reproducibility, and alignment with the needs of clinical, commercial, and investment stakeholders seeking an actionable understanding of the drug eluting balloon environment.

Concluding synthesis linking clinical innovation, evidence generation, and operational strategy as the foundation for sustainable adoption of drug eluting balloons

In conclusion, drug eluting balloons occupy a strategically important and evolving niche in vascular intervention, blending the potential for durable antiproliferative benefit with procedural simplicity that avoids permanent implants. Adoption will continue to be driven by innovation in coating chemistry and delivery systems, by rigorous clinical evidence addressing key lesion subtypes, and by practical commercial strategies that reflect the needs of diverse care settings. Tariff pressures and regional regulatory nuance add complexity to commercialization planning but also create impetus for supply chain resilience and localized manufacturing strategies.

Manufacturers and stakeholders who align technical differentiation with targeted clinical programs and who engage payers and procurement leaders early will be best positioned to capture long-term value. As the field advances, ongoing investment in transparent post-market surveillance and real-world evidence will be essential to sustaining clinician confidence and payer support. Ultimately, success in this market will depend on an integrated approach that marries scientific rigor with operational excellence and a clear focus on patient-centered outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of novel polymer-free drug coatings to reduce late adverse events in drug eluting balloon procedures
• 5.2. Emergence of sirolimus-eluting balloon technology expanding treatment options for peripheral arterial disease patients
• 5.3. Integration of intravascular imaging guidance systems with drug eluting balloon therapies for precision lesion assessment
• 5.4. Strategic collaborations between medical device manufacturers and pharmaceutical companies for optimized drug formulations on balloons
• 5.5. Growing investment in micro-poration technology to enhance local drug transfer efficiency during balloon angioplasty interventions
• 5.6. Expanding focus on health economics and reimbursement strategies to improve market access for drug eluting balloon devices
• 5.7. Rapid market growth in Asia-Pacific driven by rising incidence of peripheral artery disease and improved healthcare infrastructure

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Balloon Market, by Application

• 8.1. Coronary Artery Disease
  • 8.1.1. De Novo Lesion
  • 8.1.2. In-Stent Restenosis
• 8.2. Peripheral Artery Disease
  • 8.2.1. Below Knee
  • 8.2.2. Femoropopliteal

9. Drug Eluting Balloon Market, by Drug Type

• 9.1. Paclitaxel-Coated
• 9.2. Sirolimus-Coated

10. Drug Eluting Balloon Market, by End User

• 10.1. Ambulatory Surgical Center
• 10.2. Clinic
• 10.3. Hospital

11. Drug Eluting Balloon Market, by Product Type

• 11.1. Conventional Balloon
• 11.2. Specialty Balloon

12. Drug Eluting Balloon Market, by Distribution Channel

• 12.1. Direct
• 12.2. Distributor

13. Drug Eluting Balloon Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Drug Eluting Balloon Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Drug Eluting Balloon Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Medtronic plc
  • 16.3.2. Boston Scientific Corporation
  • 16.3.3. B. Braun SE
  • 16.3.4. Koninklijke Philips N.V.
  • 16.3.5. Becton Dickinson and Company
  • 16.3.6. Terumo Corporation
  • 16.3.7. MicroPort Scientific Corporation
  • 16.3.8. Cook Medical LLC
  • 16.3.9. Elixir Medical Corporation
  • 16.3.10. Concept Medical Research Private Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DRUG ELUTING BALLOON MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 113. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 115. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 117. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 119. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 121. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 123. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 124. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 125. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 126. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 130. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 131. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 132. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 133. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 134. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 136. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 137. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 138. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 139. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 140. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 141. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 142. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 143. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 146. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 147. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 148. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 151. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 152. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 153. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 155. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 156. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 157. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 158. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 179. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 180. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 185. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 187. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 188. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 194. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 195. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 196. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 197. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 198. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 199. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 200. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 201. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 204. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 205. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 206. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 207. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 210. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 211. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 212. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 213. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 214. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 215. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 216. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 217. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 222. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 223. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 226. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 227. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 228. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 229. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 230. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 231. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 232. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 233. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 236. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 237. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 238. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 244. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 245. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 246. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 247. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 248. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 249. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 250. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 251. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 254. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 255. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 256. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 257. GCC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GCC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GCC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 260. GCC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 261. GCC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 262. GCC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 263. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 264. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 265. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 266. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 267. GCC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 268. GCC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 269. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 270. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 271. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 274. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 275. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 276. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 277. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 278. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 279. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 280. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 281. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 282. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 283. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 285. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 287. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 288. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 289. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 292. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 293. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 294. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 295. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 296. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 297. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 298. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 299. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 300. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 301. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 302. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 303. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 304. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 305. G7 DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. G7 DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. G7 DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 308. G7 DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 309. G7 DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 310. G7 DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 311. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 312. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 313. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 314. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 315. G7 DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. G7 DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 317. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 318. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 319. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 320. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 321. NATO DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 322. NATO DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 323. NATO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 324. NATO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 325. NATO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
• TABLE 326. NATO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
• TABLE 327. NATO DRUG ELUTING BALLOON MARKET SIZE, BY PERI